5 February 2020 - USPTO issues patent on NLX-112, a Parkinson’s disease drug candidate

The United States Patent and Trademark Office (USPTO) has just issued a patent on NLX-112 (aka befiradol), a drug developed by Neurolixis for treatment of dyskinesia in Parkinson's disease. The invention is based on a clinical trial which tested sustained release formulations of NLX-112, showing that they avoided side effects of dizziness and nausea. The issuance of the patent (US 10,548,885 B2) protects NLX-112 in the US until 2035. The patent has already issued in the European Union, Canada, Australia and Russia, and is pending in other territories.

Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis commented, “We are delighted that the patent has issued in the US. Movement disorders are a major healthcare challenge, particularly among aging populations in developed nations, and this patent strengthens the commercial prospects of NLX-112 in a major pharmaceutical market.”

Full patent information: WO2016005527A1: Method for treating movement disorders with befiradol

23 October 2019 - Neurolixis' Parkinson's disease project showcased by French regional business accelerator

Neurolixis' development of NLX-112, a drug candidate for treatment of dyskinesia in Parkinson's disease and other movement disorders, was showcased by the Castres-Mazamet Technopole, a French regional entrepreneur accelerator in a video interview and article. In particular, these highlighted the recent financial support received by Neurolixis from the US Dept of Defense. The accelerator assists the French branch of Neurolixis in fundraising, recruitment and business networking.

See the full article here.